Initiation of hormone replacement therapy after diagnosis of osteoporosis by bone densitometry

Phillipov, George; Mós, Eduardo do Nascimento; Scinto, S.; Phillips, Patrick J.

doi:10.1007/bf01623693

Cited by 13 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings on BMD T-scores are consistent with several other studies [9–11, 13, 14, 16, 19]. However, previous studies looking at the association between BMD T-scores and treatment have used prospective data sources.…”

Section: Discussionsupporting

confidence: 92%

Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA

et al. 2009

View full text Add to dashboard Cite

SummaryWe identified factors associated with oral bisphosphonate treatment in 50+-year-old female patients with a first fracture, osteoporosis diagnosis, or BMD ≤−2.5 in the Geisinger Health System electronic health record database. Treatment was positively associated with age, oral corticosteroids, and smoking, and negatively associated with body mass index and bone mineral density scores.IntroductionTo identify factors associated with oral bisphosphonate treatment in patients with an indicator for post-menopausal osteoporosis.MethodsFemales age 50+ years with a first fracture, osteoporosis diagnosis, or bone mineral density (BMD) ≤−2.5 (index date) were identified in the Geisinger Health System electronic health record database. Treatment was defined as an oral bisphosphonate prescription order (risedronate sodium, ibandronate sodium, or alendronate) ≤90 days post-index date. Treatment rates were assessed and a multivariate logistic model was used to identify predictors of treatment separately for patients with fracture (FRAC) and with diagnosis or low BMD (ICD-9-BMD).ResultsThe FRAC group had 2,003 female patients with a mean (SD) age of 69.0 (±11.3) years and the ICD-9-BMD group had 12,976 female patients with a mean (SD) age of 66.9 (±10.0) years. Within 90 days of the index date of fracture, diagnosis, or low BMD score, 188 (9.4%) patients in the FRAC group and 5,395 (41.6%) in the ICD-9-BMD group received treatment. Treatment was positively associated with age and oral corticosteroids and negatively associated with body mass index and subsequent BMD in both groups. Smoking currently was positively associated with treatment in the ICD-9-BMD group.ConclusionCertain patient characteristics are predictors of physicians prescribing oral bisphosphonates. However, many patients remain untreated.

show abstract

Section: Discussionsupporting

confidence: 92%

Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA

et al. 2009

View full text Add to dashboard Cite

show abstract

“…A BMD test may help clarify the benefit‐to‐risk ratio for those women who are uncertain about initiating drug therapy. A number of studies have found that knowing the result of a BMD test influences drug prescribing and also lifestyle changes (34–41) . In these studies, women were between 3 and 16 times more likely to start or receive a prescription for hormone replacement therapy if the BMD report classified the patient as having low bone mass or osteoporosis.…”

Section: Discussionmentioning

confidence: 99%

Population Trends in BMD Testing, Treatment, and Hip and Wrist Fracture Rates: Are the Hip Fracture Projections Wrong?

Jaglal

Weller

Mamdani

et al. 2005

Journal of Bone and Mineral Research

194

133

View full text Add to dashboard Cite

A worldwide epidemic of hip fractures has been predicted. Time trends in BMD testing, bone-sparing medications and hip and wrist fractures in the province of Ontario, Canada, were examined. From 1996 to 2001, BMD testing and use of bone-sparing medications increased each year, whereas despite the aging of the population, wrist and hip fracture rates decreased.Introduction: If patients with osteoporosis are being diagnosed and effective treatments used with increasing frequency in the population, rates of hip and wrist fractures will remain stable or possibly decrease. We report here time trends in BMD testing, prescriptions for bone-sparing medications, hip and wrist fracture rates, and population projections of fracture rates to 2005 in the province of Ontario, Canada. Materials and Methods: Ontario residents have universal access to Medicare. To examine time trends in BMD testing, all physician claims for DXA from 1992 to 2001 were selected from the Ontario Health Insurance Plan (OHIP) database. Trends in prescribing were examined from 1996 to 2003 using data from the Ontario Drug Benefit plan, which provides coverage to persons Ն65 years of age. Actual numbers of hip and wrist fractures were determined for 1992-2000 and population projections for 2001-2005 using time-series analysis. Wrist fractures were identified in the OHIP database and hip fractures through hospital discharge abstracts. Results: From 1992 to 2001, the number of BMD tests increased 10-fold. There has been a steady increase in the number of persons filling prescriptions for antiresorptives (12,298 in 1996 to 225,580 in 2003) and the majority were for etidronate. For women, the rate of decline for wrist fractures is greater than that for hip fractures. The rate of hip fracture was fairly constant around 41 per 10,000 women Ն50 years between 1992 and 1996. In 1997, the hip fracture rate began to decrease, and the population projections suggest that this downward trend will continue to a rate of 33.1 per 10,000 in 2005. Conclusions: Our findings suggest that fracture rates may be on the decline, despite the aging of the population, because of increased patterns of diagnosis and treatment for osteoporosis.

show abstract

“…This observation suggests that ibandronate treatment is more effective in subjects with more serious conditions of osteoporosis and that ibandronate is useful for long-term use. However, there can be a potential selection bias in the trials’ recruitment phase of the included studies as many other studies have reported a positive relationship between the start of any treatment for osteoporosis and T scores [ 62 – 65 ]. Moreover, diagnosis and treatment rates of osteoporosis are quite low [ 66 , 67 ].…”

Section: Discussionmentioning

confidence: 99%

Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis

Ma¹,

Zhou³

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

BackgroundAim of the present study was to identify the predictors of ibandronate efficacy in subjects with osteoporosis or decreased bone mineral density (BMD).MethodSeveral electronic databases were searched by using specific keywords for the acquisition of research articles reporting the efficacy of ibandronate in subjects with osteoporosis or decreased BMD. Metaregression analyses were carried out by using changes in the BMD of lumbar spine and total hip following ibandronate treatment as dependent (outcome) variables against several independent (explanatory) variables.ResultsData were extracted from 34 studies (11,090 ibandronate treated subjects) which fulfilled eligibility criteria. A history of previous fracture/s was reported by 46% of these subjects. In overall population, longer treatment duration from 1 to 5 years, increasing age, history of previous fractures, lower baseline T score, and higher baseline levels of C-terminal telopeptide of type 1 collagen (CTX) predicted higher ibandronate efficacy in improving BMD of the lumbar spine as well as of the total hip. Lower baseline levels of vitamin D and higher baseline levels of bone specific alkaline phosphatase (BSAP) predicted higher efficacy of ibandronate for lumbar spine only. In postmenopausal women with osteoporosis or decreased BMD, in addition to above-mentioned predictors, better efficacy of ibandronate was also associated with increasing time since menopause for both lumbar spine and total hip and lower body weight for lumbar spine only.ConclusionLonger treatment duration from 1 to 5 years, increasing age, lower baseline T scores, and higher serum CTX levels are identified as the predictors of better efficacy of ibandronate in the study subjects with osteoporosis or decreased BMD.

show abstract

Initiation of hormone replacement therapy after diagnosis of osteoporosis by bone densitometry

Cited by 13 publications

References 8 publications

Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA

Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA

Population Trends in BMD Testing, Treatment, and Hip and Wrist Fracture Rates: Are the Hip Fracture Projections Wrong?

Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis

Contact Info

Product

Resources

About